HCV Genotype 1 - 6 / HCV Subtypes Variants Genotype 1 and 4 Articles Genotype 2 and 3 Articles Genotype 5 and 6 Articles
Genotypes 1 and 4 Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients - 3/21/08Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08 How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50? - 11/30/07 HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone - 5/22/07Epidemiological Characteristics and Treatment Outcomes in Individuals with Genotype 4 HCV Infection - 7/10/07 Asians with Genotype 1 HCV Respond as Well as Whites to Interferon-based Therapy - 5/25/07 Selected Patients with Genotype 1 HCV May Attain SVR by Extending Treatment Duration to 72 Weeks - 4/24/07400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV - 4/24/07Telaprevir-based Therapy for HCV May Shorten Treatment Duration from 48 to 24 Weeks for Some Genotype 1 Patients - 4/17/07 Report of Hepatitis C Virus Genotype Recombination 2/16/07Liver Steatosis in Genotype 4 Patients Is Mainly Due to Metabolic Factors - 2/09/07Distribution of Hepatitis C Virus Genotypes and Viral Load Levels in the U.S. - 8/25/0624-Week vs 48-Week Treatment with Pegasys Plus Ribavirin in HCV Genotype 1 Patient- 8/08/06 Interim Results of Studies of Albuferon plus Ribavirin in Nonresponders and in Treatment-naïve Patients with HCV Genotype 1 - 3/17/06
Genotypes 2 and 3 Genetic Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation - 2/26/08 Asians with HCV Genotype 3 Do Not Respond as Well as Caucasians to Interferon-based Therapy - 2/19/08 HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08 Insulin Resistance Linked to Lower Treatment Response in Genotype 2/3 Patients - 2/01/08 Liver Steatosis Is Common in Hepatitis C Patients, Especially Those with Genotype 3 - 2/01/08 Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08 HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08 Pegylated Interferon Alfa-2a Plus Ribavirin for 16 or 24 Weeks in Patients with Genotype 2 or 3 HCV Infection - 7/20/07 Both Pegasys/Ribavirin and PegIntron/Ribavirin Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3 Patients - 5/22/07 HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone - 5/22/07 Treatment with Pegasys Plus Ribavirin in Genotype 2/3 Chronic Hepatitis C Patients with Liver Cirrhosis - 5/22/07 Treatment Duration and Response in Patients with Genotype 2 or 3 HCV Infection - 5/01/07 14 Weeks of Treatment with PegIntron plus Ribavirin Is Non-inferior to 24 Weeks in Rapid Responders with HCV Genotype 2 or 3 - 4/20/07Past Psychiatric Disorders Do Not Reduce Hepatitis C Treatment Effectiveness in Genotype 2/3 Patients - 4/20/07Report of Hepatitis C Virus Genotype Recombination 2/16/0716-week Treatment May Be Adequate for Genotype 2 Hepatitis C Patients 9/29/06
Genotypes 5 and 6 Articles (Genotype 5 - Africa / Genotype 6 - South East Asia) Epidemiology and Treatment Response of Genotype 5 HCV; Researchers Find New Seventh Genotype - 11/27/07 HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone - 5/22/07 Does Weight-based Ribavirin Dosing Increase Sustained Viral Response in Patients with Chronic Hepatitis C? Final Results of the WIN-R Study - 11/18/05
Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6 - 10/21/05 First Report of Hepatitis C Virus Genotype 6 Infection in India - 6/22/5 The Effectiveness of Standard and Pegylated Interferon Plus Ribavirin in Treatment-naïve Patients with Chronic Hepatitis C Virus Genotype 5 in France - 5/13/05 Response to Treatment in Patients with HCV Genotype 5 - 4/25/05
